Paxlovid rebound may benefit from combining with _ _ _ in the vaccinated

The case of worsening symptoms (or becoming positive again) on completion of the course of Paxlovid after COVID-19 infection seems to be gaining more attention. In doing the research around this topic, the pathway in the image below seemed to align with a recent post on potential the benefit of hydroxycholroquine (HCQ) in selected COVID-19 cases.

If hydroxychloroquine could help with Omicron, would politics block its use?

Paxlovid is a coronavirus protease inhibitor. This viral enzyme is a critical part of making new viral particles and early use of an antiviral should therefore reduce viral spread.

Remarkably, a combination approach with hydroxychloroquine could be complementary and potentially reduce the risk of rebound. The difficulty is predicting which patients could have a rebound and whether there could be more medication interactions by combination.

Certainly worth consideration.

Paxlovid only tested for benefit in the unvaccinated